Key Points
- COO Michael Chi sold 14,027 HIMS shares at an average price of $28.39, generating approximately $398,227. The sale was made under a pre-arranged Rule 10b5-1 plan, leaving him with 456,660 shares.
- Hims & Hers reported quarterly revenue of $753.2 million, up 38.2% year over year and above analyst expectations, but its loss of $0.37 per share significantly missed the consensus estimate of a $0.05 loss.
- Analysts maintain a generally cautious outlook, with the stock carrying a consensus “Hold” rating and a $32.43 price target. The company also faces securities litigation tied to allegations involving privacy, data-sharing, billing and related disclosures.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 6,236 shares of the company's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $27.86, for a total value of $173,734.96. Following the sale, the insider directly owned 304,270 shares of the company's stock, valued at approximately $8,476,962.20. This represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Soleil Boughton also recently made the following trade(s):
- On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total value of $97,965.14.
- On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.
Hims & Hers Health Stock Down 0.3%
HIMS stock opened at $27.92 on Friday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The firm has a market capitalization of $6.51 billion, a P/E ratio of -44.32 and a beta of 2.42. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $65.30. The company's 50 day simple moving average is $30.19 and its 200-day simple moving average is $27.60.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analysts' expectations of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company's revenue for the quarter was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 earnings per share. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.
Hims & Hers Health News Summary
Here are the key news stories impacting Hims & Hers Health this week:
- Neutral Sentiment: Bank of America Securities maintained its Hold rating on HIMS, signaling limited near-term conviction despite the stock’s decline. Bank of America Hold Rating
- Neutral Sentiment: COO Michael Chi sold 14,027 shares for approximately $398,000, while insider Soleil Boughton sold 6,236 shares for about $174,000. Both transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their significance as direct bearish signals, although they add to investor concern about insider selling. SEC Insider Filing
- Negative Sentiment: Several law firms announced or promoted a federal securities class action covering investors who bought HIMS shares between August 4, 2025, and July 29, 2026. Investors have until November 2, 2026 to seek lead-plaintiff status. Class Action Deadline Notice
- Negative Sentiment: The litigation stems from allegations related to the FTC’s complaint involving Hims & Hers’ privacy, data-sharing, billing and business practices. Plaintiffs allege the company made material misstatements or omissions about these issues. The claims remain allegations and have not been proven in court. HIMS Securities Lawsuit
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on HIMS shares. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. Citigroup lowered their target price on Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th. Bank of America raised their price target on Hims & Hers Health from $30.00 to $32.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a report on Tuesday, August 11th. Finally, Barclays cut their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a research report on Friday, August 21st. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $32.43.
Read Our Latest Analysis on HIMS
Institutional Trading of Hims & Hers Health
Several large investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in shares of Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company's stock valued at $183,485,000 after purchasing an additional 608,950 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. State of Michigan Retirement System boosted its stake in Hims & Hers Health by 13.7% during the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company's stock valued at $48,549,000 after purchasing an additional 280,900 shares during the period. Norges Bank acquired a new stake in Hims & Hers Health in the 4th quarter valued at approximately $62,153,000. Finally, Clear Street Group Inc. grew its holdings in Hims & Hers Health by 23.6% in the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company's stock valued at $61,832,000 after buying an additional 363,893 shares during the last quarter. 63.52% of the stock is owned by institutional investors.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.
Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.
The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
